We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PerkinElmer Launches Workstations for Coronavirus Testing
Read MoreHide Full Article
PerkinElmer, Inc. recently launched a series of explorer workstations for SARS-CoV-2 testing, equipped to prepare and conduct up to 10,000 COVID-19 tests per day. These modular and scalable workstations will help laboratories boost SARS-CoV-2 testing capacity and deliver results swiftly.
This development is expected to drive the company’s Diagnostics segment.
More on the Workstations
Currently, many laboratories are not able to generate COVID-19 testing results in a timely manner, which increases the risk of further spread of the disease. PerkinElmer’s scalable and modular explorer automated workstations simplify testing workflows, thereby expediting SARS-CoV-2 RT-PCR and ELISA testing. The workstations enable laboratories to enhance their efficiency, while reducing the possibility of errors. Moreover, they lessen labor requirements by automating and standardizing disparate workflow steps. Additionally, they offer different degrees of automation based on workload and staffing resources.
PerkinElmer is able to deliver all workflow components starting from reagents to equipment, to consumables at the scale they need globally. This helps clinical laboratories to respond to the pandemic with more efficiency.
For investors’ notice, PerkinElmer has more than 20 years of experience in optimizing complete workflows (including reagents, equipment, and consumables) based on testing, throughput, and staffing requirements. The company’s wide array of SARS-CoV-2 offerings comprise high-output RNA extraction, RT-PCR assays, automation, ELISA, and other laboratory solutions.
Recent development
In July 2020, the company launched a dry blood spot (DBS)-based test for SARS-CoV-2 IgG using its GSP/DELFIA platform. The platform enables processing of up to 5,000 samples per day. The finger-prick sample collection device facilitates both decentralized sample collection and high-throughput testing.
Market Prospects
Per a report published on Grand View Research, the global molecular diagnostics market was valued at $9.2 billion in 2019 and is expected to reach $18.2 billion by 2027, at a CAGR of 9%. Hence, the latest development has been a well-timed one for PerkinElmer.
Price Performance
Over the past three months, shares of the company have gained 31.1% compared with the industry’s growth of 24.1%.
Zacks Rank and Other Key Picks
PerkinElmer currently sports a Zacks Rank #1 (Strong Buy).
A few other top-ranked stocks from the broader medical space include OPKO Health (OPK - Free Report) , Surmodics (SRDX - Free Report) and Merit Medical Systems (MMSI - Free Report) .
Surmodics’ long-term earnings growth rate is estimated at 10%. The company presently carries a Zacks Rank #2.
Merit Medical Systems’ long-term earnings growth rate is estimated at 11.9%. It currently carries a Zacks Rank #2.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
PerkinElmer Launches Workstations for Coronavirus Testing
PerkinElmer, Inc. recently launched a series of explorer workstations for SARS-CoV-2 testing, equipped to prepare and conduct up to 10,000 COVID-19 tests per day. These modular and scalable workstations will help laboratories boost SARS-CoV-2 testing capacity and deliver results swiftly.
This development is expected to drive the company’s Diagnostics segment.
More on the Workstations
Currently, many laboratories are not able to generate COVID-19 testing results in a timely manner, which increases the risk of further spread of the disease. PerkinElmer’s scalable and modular explorer automated workstations simplify testing workflows, thereby expediting SARS-CoV-2 RT-PCR and ELISA testing. The workstations enable laboratories to enhance their efficiency, while reducing the possibility of errors. Moreover, they lessen labor requirements by automating and standardizing disparate workflow steps. Additionally, they offer different degrees of automation based on workload and staffing resources.
PerkinElmer is able to deliver all workflow components starting from reagents to equipment, to consumables at the scale they need globally. This helps clinical laboratories to respond to the pandemic with more efficiency.
For investors’ notice, PerkinElmer has more than 20 years of experience in optimizing complete workflows (including reagents, equipment, and consumables) based on testing, throughput, and staffing requirements. The company’s wide array of SARS-CoV-2 offerings comprise high-output RNA extraction, RT-PCR assays, automation, ELISA, and other laboratory solutions.
Recent development
In July 2020, the company launched a dry blood spot (DBS)-based test for SARS-CoV-2 IgG using its GSP/DELFIA platform. The platform enables processing of up to 5,000 samples per day. The finger-prick sample collection device facilitates both decentralized sample collection and high-throughput testing.
Market Prospects
Per a report published on Grand View Research, the global molecular diagnostics market was valued at $9.2 billion in 2019 and is expected to reach $18.2 billion by 2027, at a CAGR of 9%. Hence, the latest development has been a well-timed one for PerkinElmer.
Price Performance
Over the past three months, shares of the company have gained 31.1% compared with the industry’s growth of 24.1%.
Zacks Rank and Other Key Picks
PerkinElmer currently sports a Zacks Rank #1 (Strong Buy).
A few other top-ranked stocks from the broader medical space include OPKO Health (OPK - Free Report) , Surmodics (SRDX - Free Report) and Merit Medical Systems (MMSI - Free Report) .
OPKO Health’s long-term earnings growth rate is estimated at 12%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Surmodics’ long-term earnings growth rate is estimated at 10%. The company presently carries a Zacks Rank #2.
Merit Medical Systems’ long-term earnings growth rate is estimated at 11.9%. It currently carries a Zacks Rank #2.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>